AU2012222074A1 - Chalcone derivatives as Nrf2 activators - Google Patents

Chalcone derivatives as Nrf2 activators Download PDF

Info

Publication number
AU2012222074A1
AU2012222074A1 AU2012222074A AU2012222074A AU2012222074A1 AU 2012222074 A1 AU2012222074 A1 AU 2012222074A1 AU 2012222074 A AU2012222074 A AU 2012222074A AU 2012222074 A AU2012222074 A AU 2012222074A AU 2012222074 A1 AU2012222074 A1 AU 2012222074A1
Authority
AU
Australia
Prior art keywords
och
disease
compound
nrf2
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012222074A
Other languages
English (en)
Inventor
Shyam Biswal
Kim JUNG-HYUN
Sarvesh Kumar
Vineet Kumar
Sanjay V. Malhotra
Rajesh THIMMULAPPA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
National Institutes of Health
Original Assignee
Johns Hopkins University
National Institutes of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, National Institutes of Health filed Critical Johns Hopkins University
Publication of AU2012222074A1 publication Critical patent/AU2012222074A1/en
Assigned to THE JOHNS HOPKINS UNIVERSITY, NATIONAL INSTITUTES OF HEALTH reassignment THE JOHNS HOPKINS UNIVERSITY Request for Assignment Assignors: THE JOHNS HOPKINS UNIVERSITY
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
AU2012222074A 2011-02-25 2012-02-27 Chalcone derivatives as Nrf2 activators Abandoned AU2012222074A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161446716P 2011-02-25 2011-02-25
US61/446,716 2011-02-25
US201161500272P 2011-06-23 2011-06-23
US61/500,272 2011-06-23
PCT/US2012/026744 WO2012116362A2 (en) 2011-02-25 2012-02-27 Chalcone derivatives as nrf2 activators

Publications (1)

Publication Number Publication Date
AU2012222074A1 true AU2012222074A1 (en) 2013-09-12

Family

ID=46721498

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012222074A Abandoned AU2012222074A1 (en) 2011-02-25 2012-02-27 Chalcone derivatives as Nrf2 activators

Country Status (6)

Country Link
US (1) US20140088052A1 (enExample)
EP (1) EP2678305A4 (enExample)
JP (1) JP2014510064A (enExample)
AU (1) AU2012222074A1 (enExample)
CA (1) CA2827990A1 (enExample)
WO (1) WO2012116362A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2839301C (en) 2011-06-15 2021-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
WO2015187934A1 (en) * 2014-06-06 2015-12-10 Cureveda, Llc Functionalized hetroaryl enones exhibiting nrf2 activation and their method of use
ES2570452B1 (es) * 2014-10-15 2017-04-19 Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
MA40990A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
WO2016153432A1 (en) * 2015-03-23 2016-09-29 Nanyang Polytechnic Drugs from substituted phenyl cinnamyl ketones
EP3464236A4 (en) * 2016-05-26 2020-01-08 The Regents of the University of California CONNECTIONS AND METHOD FOR HEMATOPOIETIC REGENERATION
AR110590A1 (es) * 2016-12-27 2019-04-10 Biogen Ma Inc Activador de nrf2
CN107056707B (zh) * 2017-01-23 2019-08-23 温州医科大学 一种3,4,5-三甲氧基苯类化合物及其在制备抗氧化药物中的应用
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
WO2020094767A1 (en) * 2018-11-08 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of nrf2 activators for the treatment of staphylococcus aureus infections
CN111792990A (zh) * 2019-04-09 2020-10-20 中国科学院上海药物研究所 一种不饱和酮类化合物、其制备方法和用途
WO2021183908A1 (en) * 2020-03-13 2021-09-16 The Trustees Of Columbia University In The City Of New York Gpx4 compounds and compositions and methods of treatment using same
KR20230129258A (ko) * 2021-01-07 2023-09-07 필립모리스 프로덕츠 에스.에이. 아나타빈을 포함하는 조성물 및 이의 용도
WO2023285691A1 (en) * 2021-07-15 2023-01-19 Allspim Compositions and methods for preventing and/or treating disease associated with il-23 expression
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions
CN115572255A (zh) * 2022-04-29 2023-01-06 无锡捷化医药科技有限公司 一种查尔酮类化合物的制备方法
CN119677514A (zh) * 2022-07-29 2025-03-21 益特瑞恩公司 雌激素化合物和使用方法
CN115433073B (zh) * 2022-08-15 2024-04-19 兰州大学 一种卡瓦胡椒素b类似物的制备方法及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0740105B2 (ja) * 1986-03-14 1995-05-01 清蔵 宮田 非線形光学素子
JPH02178249A (ja) * 1988-12-28 1990-07-11 Mitsubishi Kasei Corp 光学活性ケトンの製造法
US20030065039A1 (en) * 1997-06-26 2003-04-03 Statens Serum Institute Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
ATE248583T1 (de) * 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
WO2000018390A1 (fr) * 1998-09-28 2000-04-06 Hsp Research Institute, Inc. Inducteurs d'expression de proteine de choc thermique
AU2002335040A1 (en) * 2001-10-16 2003-04-28 Atherogenics, Inc. Protection against oxidative stress and inflammation by a cytoprotective response element
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
KR100830541B1 (ko) * 2006-08-11 2008-05-21 충남대학교산학협력단 인터루킨-5 저해효과를 갖는 신규 찰콘계 유도체

Also Published As

Publication number Publication date
WO2012116362A3 (en) 2012-11-29
EP2678305A2 (en) 2014-01-01
CA2827990A1 (en) 2012-08-30
EP2678305A4 (en) 2015-11-04
WO2012116362A2 (en) 2012-08-30
JP2014510064A (ja) 2014-04-24
US20140088052A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
US20140088052A1 (en) Chalcone derivatives as nrf2 activators
Kumar et al. Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells
Yang et al. Pterostilbene prevents LPS-induced early pulmonary fibrosis by suppressing oxidative stress, inflammation and apoptosis in vivo
Zhao et al. Black rice anthocyanin-rich extract and rosmarinic acid, alone and in combination, protect against DSS-induced colitis in mice
Treasure et al. Exploring the anti‐inflammatory activity of sulforaphane
Lv et al. Salvianolic acid B attenuates apoptosis and inflammation via SIRT1 activation in experimental stroke rats
CN109640967B (zh) 抑制胆碱向三甲胺(tma)的转化的方法
Tian et al. Minocycline alleviates sevoflurane-induced cognitive impairment in aged rats
US20090192227A1 (en) N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
CN105163728B (zh) 包含蜂胶提取物的治疗性组合物和其用途
US20220088107A1 (en) Method for treating or preventing inflammation
CN112336736A (zh) 开环异落叶松脂素二葡糖苷(sdg)和相关化合物用于防护辐射和化学损害的用途
Manjunath et al. Development of Moringa oleifera as functional food targeting NRF2 signaling: Antioxidant and anti-inflammatory activity in experimental model systems
JP6126592B2 (ja) 前立腺癌の治療又は予防用のブロッコリー種子抽出物含有組成物
CN103857400A (zh) 玫瑰红景天提取物和分离的化合物及其在治疗神经变性疾病中的应用
US9730970B2 (en) Seaweed extracts, unsaturated aldehydes, and methods of treatment
CA2930606C (en) Methods for suppressing cancer-related cachexia
CA2662636C (en) N-acetylcysteine compositions and methods for treating acute exacerbations of inflammatory lung disease
JP6912875B2 (ja) ＥｒｂＢ４＋炎症性マクロファージによって媒介される疾患の治療方法
US12599584B2 (en) Indoline derivatives, compositions comprising them and uses thereof
KR102618160B1 (ko) 람부탄 씨 추출물, 분획물 또는 이로부터 분리된 플라보노이드를 세노모르픽 제제의 유효성분으로 함유하는 세포의 노화 관련 증상 억제 및 노화 관련 질환을 예방 또는 치료하는 조성물
Benmaarouf et al. In vivo acute toxicity, analgesic activity and phytochemical characterization of Solenostemma argel (Del) Hayne essential oil
WO2014049044A1 (en) Methods and pharmaceutical compositions for the treatment of ulcerative colitis
Mahalanobish et al. Chronic Obstructive Pulmonary Disease: Molecular Basis of Pathogenesis and Targeted Therapeutic Approaches
Mahalanobish et al. and Targeted Therapeutic Approaches

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: THE JOHNS HOPKINS UNIVERSITY; NATIONAL INSTITUTES

Free format text: FORMER APPLICANT(S): THE JOHNS HOPKINS UNIVERSITY

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application